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94 M.A. AL-Kamarany et al.laboratory A (accredited laboratory) to a receiving laboratory B. The HPLCmethod for the determi-
nation of the percent release of diclofenac sodium in solid pharmaceutical forms (one is the discovered
product and another generic)was validatedusing accuracy proﬁle (total error) in the sender laboratory
A. The results showed that the receiver laboratory B masters the test dissolution process, using the
sameHPLCanalytical procedure developed in laboratoryA. In conclusion, if the sender used the total
error to validate its analytical method, dissolution test can be successfully transferred without
mastering the analytical method validation by receiving laboratory B and the pharmaceutical analysis
method state should be maintained to ensure the same reliable results in the receiving laboratory.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The transfer of analytical methods of pharmaceuticals plays
important roles within the pharmaceutical industry. Transfer-
ring the methods is now a challenging step during the life cycle
of the analytical method. It is considered the last step before
the routine use of the method at the receiving laboratory.
The receiver must therefore guarantee of their capacity to
implement the method and importantly being able to obtain
reliable results (Rozet et al., 2009).
An analytical transfer is a complete process that consists in
transferring a validated analytical method from a sending lab-
oratory (called sender) to a receiving laboratory (called recei-
ver) after experimentally demonstrating the capability to
master the method (Dewe´ et al., 2007). Veriﬁcation of a test
method’s acceptability should be performed for all methods.
When a test method is transferred to an alternative testing site
requires evidence that the test procedure is functioning cor-
rectly (Stephen et al., 2002).
The transfer protocol or test plan should include suitable
acceptance criteria relevant to the tests and speciﬁc dissolution
proﬁles where dissolution is a characterization test commonly
used by the pharmaceutical industry to guide formulation de-
sign. Also, it is used to control product quality and it is consid-
ered a key parameter in assessing the uniformity at the
formulation stage as well as throughout the shelf-life of the
product (Cohen et al., 1990).
Due to lack of formal guidance or regulatory requirements,
several approaches are possible to select the experimental de-
sign, for choosing the statistical data treatment and hence for
the decision process namely the dissolution test (Fontenay,
2008). The success of an analytical method transfer is tested
by comparing results or their summary parameters such as the
means and variances of the participating laboratories obtained
after analyzing similar samples. Therefore, it is important for
the researchers to search ways to validate the analytical transfer.
Several terms and statistical approaches for the transfer of
analytical methods have been described and designed. The
USP (2009) described the transfer of analytical procedures:
A proposal for a new general information chapter 1224. Also
the FDA (2006) has released an ofﬁcial guidance on how to
conduct and document method transfer. The ISPE (The Inter-
national Society for Pharmaceutical Engineering) design pro-
vides adequate probabilities to accept successful method
transfers correctly only for relatively small error amounts
(Schepers and Wa¨tzig, 2005; Kaminski1 et al., 2010). Also
the conventional statistical approaches generally were used in
the transfer of quantitative methods namely bioanalytical
applications associated with risk evaluation of this transfer
(Rozet et al., 2008). On the other hand, the United StatesPharmacopoeia concept (1010) was used as the equivalence test
for analytical method transfer (Schepers andWa¨tzig, 2006) and
it uses total error as a decision criterion for transfer of HPLC–
UV method (Rozet et al., 2006). The best way to estimate the
characteristics of dispersion of anHPLCmethod and a powerful
tool for analytical transfers was studied (Vial and Jardy, 2001).
The objective of this work is to demonstrate the applicabil-
ity of the total error approaches with certain statistical models
to a more variability domain pharmaceutical namely dissolu-
tion test and in the interpretation of acceptance criteria of
transfer of dissolution proﬁles of solid pharmaceutical form.
2. Materials and methods
2.1. Standard and placebo
The reference standard (RF) for diclofenac sodium (DS)
(98.2%) was obtained from Drugs Quality Control Laboratory
as certiﬁed by external secondary standard. The product A as
originator was obtained from Novartis for pharmaceutical
industries and product B as generic was obtained from
Galanica for pharmaceutical industries (Morocco). The
placebos used in validation of the analytical method were the
fallowing: calcium phosphate tribasic, sodium starch glycolate,
magnesium stearate, polyvinylpyrrolidone, microcrystalline
cellulose, sucrose, puriﬁed talc, disperse red, lactose, selenium
dioxide, cellulose acetophthalate, titanium dioxide, ethanol,
polyethylene glycol, iron oxide red, iron oxide yellow, maize
starch, silica colloidal anhydrous, silicone antifoam, sodium
methyl carboxyl and polysorbate 80.
2.2. Reagents
At the sending and receiving sites, methanol was of HPLC grade
fromSigma–Aldrich (Germany).Hydrochloric acidandphospho-
ric acidwere supplied byMerckKGaA (Germany). Sodiumphos-
phate tribasic was obtained from Riedel-de Haen (Germany).
2.3. Apparatus
At the sending site, the chromatographic system consisted of
Waters 2695 pump, auto sampler and Waters 2998 photodi-
ode-array detector (PDA). Data acquisition was performed
by the Empower Software data registration TM. Dissolution
test of Erweka DT 600, Frankfurt (Germany). pH meter of
Concort (Belgium). Balance of Precisa (Switzerland).
At the receiving site, Dissolution test of Hanson SR8-Plus
(USA), the chromatographic system consisted of Waters 2695
pump, auto sampler and Waters 2998 photodiode-array detec-
tor (PDA). Data acquisition was performed by the Empower
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(Switzerland). pH meter of Schott (Germany).
2.4. Chromatographic conditions
At the sending and receiving sites, the chromatographic system
and conditions were as follows: Waters YMC C18 3 lm
150 cm · 4.6 mm and phenomenex C18 3 lm 150 cm ·
4.6 mm columns, respectively; eluent: buffer (pH=2.5, 0.5 g/l
phosphoric acid 1.4 g/l sodium phosphate monobasic dihy-
drate and /MeOH (30/70 v/v)). The mobile phase was ﬁltered
through a 0.45-lmMillipore TM Durapore ﬁlter and degassed
by vacuum prior to use. The ﬂow rate was 1 ml/min and the
injection volume was 20 ll with a temperature of 30 C. The
wavelength of the detector was set at 276 nm.
2.5. Validation of the analytical method at the sending
laboratory
2.5.1. Preparation of assay validation
In order to validate the analytical method, two kinds of samples
were prepared in an independent way: calibration standards and
validation standards. In the calibration standards (CSs), sam-
ples were prepared in seven known concentrations with two as-
says as the following: dissolve an accurately weighed standard
DS in diluent A (water and methanol, 30 ml:70 ml) speciﬁcally
0.5411, 1.090, 5.486, 13.54, 46.33, 54.81 and 68.38 mg/100 ml
without matrix (placebo). Samples were shaken by mechanical
means for 10 min and sonicated for about 10 min. Five millili-
ters from stock standards was transferred into a volumetric
50 ml ﬂask and it was completed by diluent B namely medium
dissolution (the dissolution medium used in the validation was
prepared as follows: sodium phosphate tribasic (76 g/l) and
hydrochloric acid 0.1 N (250 mg and 750 ml) were mixed and
the pH was adjusted to 6.8 ± 0.05 by hydrochloric acid 2 N.
Seven concentrations (0.0005411, 0.001090, 0.005486, 0.01354,
0.04633, 05481 and 0.06838 mg/ml) were obtained. Those solu-
tions were ﬁltered using a 0.45-lm ﬁlter. The validation stan-
dards (VSs) were prepared as the calibration standard with
matrix (placebo) with three assays. The evaluation of the HPLC
method speciﬁcity was performed by preparing placebo tablets
containing the same excipients of the commercial products
(United States Pharmacopeia, 2009; Hubert et al., 2003;
International Conference, 2005; ISO/IEC, 2005).
2.5.2. Computation analysis
The data obtained were treated and computed using e-Novel
software (Arlenda, Belgium). A linear regression model
(through zero using the highest level only) is ﬁtted on the
back-calculated concentrations as a function of the introduced
concentrations in order to obtain the following Eq. (1), where
Y= back-calculated concentrations (mg/ml) and X= intro-
duced concentration (mg/ml) (Hubert et al., 2003):
Y ¼ aXþ b ð1Þ
Trueness is expressed in terms of absolute bias (Ab) (mg/ml),
% relative bias (Rb) or % recovery (R) at each concentration
levels of the validation standards. Those terms were calculated
based on Eqs. (2)–(4) (Miller and Miller, 2000; ISO, 1994). l^ is
the mean of the introduced concentrations and x^ is the esti-
mate of the mean concentration obtained from calculated con-
centrations then we have:Ab ¼ x^ l^ ð2Þ
Rb ð%Þ ¼ 100 x^ l^
l^
ð3Þ
R ð%Þ ¼ 100 x^
l^
ð4Þ
An accuracy proﬁle is obtained by linking on the one hand
the lower bounds and on the other hand the upper bounds
of the b-expectation tolerance intervals calculated at
each concentration level (Hubert et al., 2003; Mee, 1984).
The formula to compute these b-expectation tolerance
intervals is
bias ð%Þ  kRSDIP ð%Þ ð5Þ
RSDIP ð%Þ ¼ 100
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r^2B þ r^2W
p
l
ð6Þ
k ¼ Qt v;
1þ b
2
  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ nr^
2
B þ r^2W
pn r^2B þ r^2Wð Þ
s
ð7Þ
v ¼ ðRþ 1Þ
2
Rþ1nð Þ2
p1 þ
11n
pn
ð8Þ
where r^2B and r^
2
B are the estimates of the between-series and
within-series variances, respectively, Qtðv; 1þb2 Þ is the b quan-
tile of the Student’s distribution with v degrees of freedom
and v is the Satterthwaite’s approximation of the degrees
of freedom; where R is the ratio of the between-series over
the within-series variance; p is the number of series and n
the number of repetitions per series, then n is estimated
by the average number of repetitions. On the other hand
the intermediate precision standard deviation (SD) was cal-
culated by using the following equation (Chapuzet et al.,
1997; Hubert et al., 1999):
SIP ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r^2B þ r^2W
q
ð9Þ
The limit of detection is the smallest quantity of the targeted
substance that can be detected based on Eq. (10). While the
lower limit of quantitation (LOQ) was assayed under experi-
mental conditions (Hubert et al., 2003):
LOD ¼ LOQ
3:3
ð10Þ
The risk of having measurements outside the acceptance limits
is directly derived from the above Tolerance Interval, using the
same estimates and t distribution in a different manner, i.e. by
computing the probability to be above the upper acceptance
limit plus the probability of being below the lower acceptance
limit instead of computing the interval where it is expected to
observe b% of the future measurements (Mee, 1988). The
probability to have measurements outside the acceptance limit
can be expressed as follows:
P XilTlT
  > kh i ¼ P XilTlT < ðkÞ
h i
þ P XilTlT > ðþkÞ
h i
P ¼ tðvÞ < kð%Þbiasð%Þ
RSDIP
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ nr
2
B
þr2
W
pnðr2
B
þr2
W
Þ
r
2
664
3
775þ P tðvÞ > kð%Þbiasð%Þ
RSDIP
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ nr
2
B
þr2
W
pnðr2
B
þr2
W
Þ
r
2
664
3
775
ð11Þ
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value, p is the number of series and n is the number of rep-
etitions per series, k is the acceptance limit, m is the
Satterthwaite’s approximation of the degrees of freedom,
RSDIP is the relative standard deviation of the intermediate
precision.
2.6. Dissolution proﬁle at the sending laboratory
The dissolution rate studies on conventional DS tablets
50 mg namely reference (product A) and generic (product
B) were carried out according to USP paddle method
(Apparatus 2), at a stirring rate of 50 rpm for 45 min. The
dissolution medium was 900 ml of buffer solution 6.8 at
37 ± 0.05 C (United States Pharmacopeia, 2009). The disso-
lution medium used in the validation was prepared as fol-
lows: sodium phosphate tribasic (76 g/l) and hydrochloric
acid 0.1 N (250 mg and 750 ml) were mixed and then the
pH was adjusted to 6.8 ± 0.05 by hydrochloric acid 2 N.
Two milliliters of sample aliquots was withdrawn at 10, 20,
30 and 45 min using a glass syringe and ﬁltered through
0.45-lm membrane ﬁlters. The dissolved amount was deter-
mined by a validated method namely HPLC–UV detection
and it was compared with a standard solution having a
known concentration.
2.7. Transfer of dissolution proﬁle
2.7.1. Experimental design at the sending and receiving
laboratories
Theprotocol of transfer of dissolutionproﬁles (kinetic ofDS)was
designed in three days for two products namely one reference
(productA) andone generic (productB). For each day, six tablets
weremeasured.The timepoints used indissolutionwere10, 20, 30
and 45 min as the same time points and dissolution condition of
the sender laboratory. In the protocol of dissolution test transfer
was used 18 tablets (units) for the same lot of products. The pro-
tocol was applied with different apparatus and operator. The
data obtained from transfer were calculated by using Microsoft
Excel software and Minitab Statistical Software 15.
2.7.2. Statistical approaches for transfer of drugs dissolution
testing
The dissolution test has high variability (Qureshi and Shab-
nam, 2001) in results, therefore certain statistical approaches
were applied for transfer of drugs dissolution allowing appro-
priate possibility of selection of the experimental design.
Descriptive statistics was used to describe the basic features
of the data in the dissolution study. These approaches provide
simple summaries about the sample and the measures. The
central tendency, desperation and the percent coefﬁcient of
variation (% CV) of sender and receiver labs were measured.
The conﬁdence interval of a standard deviation (CIr) and
the conﬁdence interval of a coefﬁcient of variation of precision
intermediate (CICVIP ) of the sender laboratory were calculated
based on Eqs. (13) and (15), respectively. Also, the standard
deviation (r) and the coefﬁcient of variation of precision inter-
mediate (CVIP) of the receiver laboratory were measured based
on Eqs. (12) and (14) (Mallet et al., 2010; Pierre, 2007):
r ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N 1
Xn
i¼1
ðXi  XÞ2
s
ð12ÞCIr ¼ r
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðN 1Þ
x2ð1r=2Þ
s
; r
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðN 1Þ
x2ðr=2Þ
s" #
ð13Þ
CVIP ¼ 100
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r2W  r2B
p
x
v ð14Þ
CIðCVIPÞ ¼ CVIP 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðN 1Þ
x2ð1r=2Þ
s
;CVIP 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðN 1Þ
x2ðr=2Þ
s" #
ð15Þ
where x2ð1r=2Þ is the percentile of a chi-square distribution with
degrees of freedom (to calculate the 95% the CIr and the
CICVIP , the region under the x
2 distribution that equates to
95% is found between and x2 0.025 and x2 0.975), r^2W is a var-
iance inter-series (reproducibility). r^2B is a variance intra-series
(repeatability), n is a number of assay in one series, N is the
number of assays in three series. x
v
is general mean of three ser-
ies .
Difference (f1) and similarity (f2) tests were applied to the
dissolution data. The difference (f1) factor is proportional to
the average difference between the two proﬁles, whereas simi-
larity (f2) factor is inversely proportional to the average
squared difference between the two proﬁles with emphasis on
the larger difference among all the time points. The values of
f1 and f2 factors for products of sender lab versus products
of receiver lab were calculated from the means of percent dis-
solved at each time point. The difference factor f1 and the sim-
ilarity factor f2 of originator drugs of the sender laboratory
versus originator drugs of the receiver laboratory as well as
generics drugs of sender lab versus generic drugs of receiver
laboratory based on validated method were calculated by
using the following equations (Food and Drug Administra-
tion, 1997):
f1 ¼ 100
Pn
i¼1jPsPrjPn
i¼1
Ps
ð16Þ
f2 ¼ 50 log 100 1þ 1=n
Xn
i¼1
ðPs  PrÞ2
" #0:58<
:
9=
; ð17Þ
where Ps is a mean of drug release percentage of sender lab
with the time point and Pr is a mean of drug release percentage
of receiver lab with the time point, then n is the number of
time.
For knowing the mechanism of drug release at sender and
receiver labs from these formulations, the data were ﬁtted to
(Korsmeyer’s log cumulative percentage of drug released
versus log time) (Costa, 2001; Dash et al., 2010):
Mt ¼M1 ¼ atn ð18Þ
Where Mt is the amount of drug released at time t, M1 is the
amount of drug released after inﬁnite time (total drug in a dos-
age form), a is the Korsmeyer’s dissolution rate constant and n
is the release exponent.
The R-chart control approach was used to monitor over
time the dispersion of dissolution test of sender laboratory
based on Eqs. (19) and (20) and rang (R) of receiver laboratory
was measured, where the R is the center line of the average
size, upper control limit (UCL) and lower control limit
(LCL) are represented. The factors D3 and D4 depend only
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1997):
LCL ¼ D3R ð19Þ
UCL ¼ D4R ð20Þ3. Results and discussion
3.1. Validation based on total error approaches
RP–HPLC/UV method was developed and validated based on
the accuracy proﬁles (total error) for the determination of DS
release in solid pharmaceutical forms at the sending labora-
tory. The speciﬁcity test by HPLC/UV demonstrated that the
excipients from tablets did not interfere in the drug peak and
the selectivity of detection was ensured by determining the
retention time of DS.
In order to ﬁnd the most suitable regression model, sev-
eral response functions (standard curves) were ﬁtted namely:
the weighted (1/X2) quadratic regression, weighted (1/X2) lin-
ear regression, weighted (1/X) linear regression, linear regres-
sion after square-root transformed data, weighted (1/X)
quadratic regression, linear regression after log transformed
data, quadratic regression, linear regression through zero ﬁt-
ted using level 1.0 only and linear regression through 0 ﬁtted
using the highest level only and the last model as a simple
model (Y= aX+ b) was selected for routine analysis. AlsoTable 1 Results of the validation of the method dedicated to the de
regression model through 0 ﬁtted with high concentration.
Response functions Day 1
Slope 4.3743E + 07
R2 ND
RSS 5.2488E + 04
Trueness Absolute bias (mg/ml)
0.5411 · 103 0.00788 · 103
1.090 · 103 0.00774 · 103
5.486 · 103 0.00372 · 103
13.54 · 103 0.02287 · 103
46.33 · 103 0.08698 · 103
54.81 · 103 0.05112 · 103
68.38 · 103 0.02388 · 103
Accuracy b-expectation conﬁdence limits (mg/
0.5411 · 103 [0.0005423, 0.0005557]
1.090 · 103 [0.001096, 0.001099]
5.486 · 103 [0.005477, 0.005502]
13.54 · 103 [0.01352, 0.01362]
46.33 · 103 [0.04601, 0.04683]
54.81 · 103 [0.05481, 0.05491]
68.38 · 103 [0.06833, 0.06848
Precision Repeatability (RSD %)
0.5411 · 103 0.5058
1.090 · 103 0.05420
5.486 · 103 0.03666
13.54 · 103 0.1501
46.33 · 103 0.3635
54.81 · 103 0.03879
68.38 · 103 0.03836the validation phase was completed by the investigation of
the risk proﬁles of various acceptable regression models in
order to avoid obtaining measurements outside the accep-
tance limits ﬁxed a priori in the sender laboratory. There-
fore, the transfer of analytical method does not need
revalidation at the receiving laboratory. This approach gives
enough guarantee that each of the future results, generated
by this method during routine use, will be close enough to
the true value. Accuracy proﬁle obtained for the validation
of the HPLC–UV analytical method for the quantiﬁcation
of DS release is considering the linear regression through
zero ﬁtted using the highest level. The accuracy proﬁle meth-
odology uses only one statistical decision methodology,
namely a b-expectation tolerance interval. The acceptance
limits were settled to ±5% and considered the ﬁrst order
risk of 5%. All the response functions allowed demonstrat-
ing the capability of the method to quantify DS over the
whole concentration range chosen and this is because the
tolerance intervals were totally included inside the accep-
tance limits. The systematic errors namely trueness at each
concentration level were expressed by absolute bias (mg/
ml), relative bias (%) and recovery (%). Differently, the
random errors were evaluated by standard deviation (SD)
and relative standard deviation (% RSD) values for repeat-
ability and intermediate precision at each concentration le-
vel. On other hand, the total errors namely systemic and
random were expressed by accuracy parameter (Table 1
and Fig. 1).termination of DS percent release in tablets form using the linear
Day 2 Day 3
4.3776E + 07 4.3763E + 07
ND ND
3.2527E + 06 2.4398E + 06
Relative bias (RSD %) Recovery (%)
1.457 101.5
0.7097 100.7
0.06773 100.1
0.1688 100.2
0.1877 100.2
0.09326 100.1
0.03492
ml) (%) Risk (%)
[0.2195, 2.694] 0.009647
[0.5771, 0.8423] 0
[0.1641, 0.2996] 0.0005163
[0.1984, 0.5360] 0.00000020
[0.7017, 1.077] 0.0001634
[0.002924, 0.1894] 0
[0.07248, 0.1423] 0
Intermediate precision (RSD %)
0.5058
0.05420
0.06598
0.1501
0.3635
0.03916
0.04197
Figure 1 Accuracy proﬁle obtained for the validation of the
HPLC–UV analytical method for the quantiﬁcation of DS release
by considering: linear regression through 0 ﬁtted using the highest
level only. Plain line: relative bias; dashed lines: b-expectation
tolerance limits; dotted curves: acceptance limits (%) and dots:
relative back-calculated concentrations of the validation
standards.
Figure 2A Dissolution proﬁle of product A at sender and
receiver laboratories.
98 M.A. AL-Kamarany et al.Seven calibration standards for DS were prepared in order
to evaluate the relationship between the area under the curve
and the concentration. The linearity of the relationship was
evaluated in a concentration range of 0.5411 · 103 mg/ml–
68.38 · 103 mg/ml, covering the normal range of concentra-
tions obtained when analyzing release of DS in tablet with
slope (1.011), intercept (0.000011), R2 (correlation coefﬁcient)
equal 1.0 and RSS (residual sum of squares) (0.00000027) .
The limit of detection (LOD) of the developed method was
equal to 0.08200 · 10–3 mg/ml, while the lower limit of quanti-
tation (LOQ) was equal to 0.5411 · 10–3 mg/ml and the upper
LOQ was equal to 68.38 · 10–3 mg/ml based on computation
analysis.
3.2. Transfer of dissolution proﬁle
The transfer of validated method based on accuracy proﬁle
that designated the simultaneous combination of systematic
(measured by biases, i.e. method trueness) and random errors
(measured by relative standard deviation ‘‘RSD’’, i.e. method
precision) associated with ISO 17025 (sender accredited labo-
ratory) gives enough guarantee for the future results. On the
other meaning, the generated results using the current methodTable 2 Descriptive criteria to accept the transfer.
Lab Sender lab R
Days Day 1 Day 2 Day 3 Inter-days D
Mean (%)
A 101.16 99.79 102.21 101.06 9
B 102.71 102.72 103.75 103.06 1
CV (%)
A 1.32 1.73 1.74 1.82 1
B 0.81 1.29 2.09 1.49 1during routine use will be close enough to the true value.
Therefore, dissolution test can be successfully transferred with-
out mastering the analytical method or revalidation by the
receiving laboratory.
3.2.1. Descriptive approach
The dissolution results of DS as the means of percent dissolved
versus time between sender and receiver laboratories are
shown in Table 2 and Fig. 2. The comparison of dissolution
proﬁles of mean three series of the two labs (each data point
represents a mean of 18 measurements for each product).
The results of the percent release of product A in solid form
of sender laboratory are 14.55%, 61.55%, 93.56% and
103.09% for the time 10, 20, 30 and 45 min, respectively.
While, the percent release of product A of receiver laboratory
is 14.01%, 56.76%, 90.02% and 97.23% for time point of 10,
20, 30 and 45 min, respectively. The percent release of product
B of sender lab is described at 10, 20, 30 and 45 min and was
50.8%, 95.04%, 102.72% and 103.06%, respectively. The per-
cent release of product B of receiver method was 52.70%,
96.58%, 98.30% and 100.19%, respectively at the same time
point. Results of dissolution show that products A and B of
sender and receiver laboratories are rapidly dissolving and dis-
solution amount is greater than Q-value of USP namely 75%
at 45 min. The transfer of the dissolution method is accepted
even though using two different conditions and different appa-
ratus as well as different operators. Also, dissolution amount is
greater than 85% at 30 min in media of sender and receiver
laboratories with pH 6.8, therefore the transfer is accepted
based on WHO norm. Where Q (single point value) is the
amount of dissolved active ingredient speciﬁed in the individ-
ual monograph, expressed as a percentage of the labeled con-
tent (Carlos et al., 2004; World Organization Health, 2005).eceiver lab Accept criteria
ay 1 Day 2 Day 3 Inter-days
6.625 99.18 97.353 97.72 Q-value > 75%
00.89 99.48 101.48 100.62
.17 3.36 1.60 2.38 CV< 10%
.49 0.92 1.29 1.44
Figure 2B Dissolution proﬁle of product B at sender and
receiver laboratories.
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test takes into account the variability of the method; therefore
the % CV of dissolution rate associated with the time namely
during 10, 20, 30 and 45 min were observed and measured in
two laboratories. The % CV of DS releases at the beginning
point (10 min) in two labs was less than 20% and the % CV
of DS releases at the ﬁnal point (45 min) in two labs was less
than 10%. These results due to the transfer are accepted based
on FDA (Food and Drug Administration, 1997) (Mallet et al.,
2010) (Table 2).
3.2.2. Repeatability and reproducibility approach
The repeatability and precision intermediate of dissolution
proﬁle of sender laboratory as characteristic of the quality
were calculated for evaluating the competence of the labora-
tory in performing measurements. The transfer of drugs disso-
lution testing is accepted because of the SD of receiver
laboratory according to the limit of CIr of sender laboratory
and the CVIP of receiver laboratory according to the limit of
CICVIP of sender laboratory (Table 3).
3.2.3. Bioequivalence in vitro approach
The results of f1 and f2 of product A (originator) of sender lab
versus product A (originator) of receiver laboratory are 4.04
and 66.12, respectively. While the results f1 and f2 of productTable 3 Repeatability and reproducibility to accept the transfer.
Lab Sender lab CIr r receiver lab
Day 1 Day 2 Day 3
Product
A 1.21 6 r 6 2.41 1.133 3.237 1.558
B 1.08 6 r 6 2.16 1.45 0.911 1.31
Table 4 Bioequivalence in vitro to accept the transfer.
Days Day 1 Day 2
f1 f2 f1 f
Product
A 8.2 57.41 0.24 7
B 0.40 74.12 4.54 6
Accept criteria f1 = (0–15), f2 = (50–100)B (generic 1) of sender laboratory versus product B (generic)
of receiver laboratory are 2.04 and 68.70, respectively. Both
of the results are within normal range (0–15) and (50–100)
(Food and Drug Administration, 1997) (Table 4). Also, it is
considered normal value based on FDA (or equivalent statisti-
cal criterion). This result indicates the acceptance of the
bioequivalence in vitro and transfer of dissolution test.
3.2.4. Drugs mechanism in vitro approach
The kinetic ofDS originator release from 50 mg tablets (product
A) based on USP condition and the application Korsmeyer’s
model are shown in Table 5. This model gives an indication of
the type of drug mechanism of release in vitro within inter-
laboratories. To conﬁrm the diffusion mechanisms, the data
were ﬁtted into Korsmeyer’s equation and the results showed
good linearity of product A for sender and receiver laboratories
(R2: 0.8963 and 0.9076, respectively, with high slope value (n) of
1.334 and 1.3057, respectively). These (n) values appear to indi-
cate super case-II transport. On other hand, the model was used
to know themechanism release of Generic (product B) of sender
and receiver laboratories. In Korsmeyer’s plot theR2 values ob-
tained are 0.8097 and 0.7761, respectively; and for that of n val-
ues are 0.4822 and 0.4563. These (n) values appear to indicate
anomalous (non-Fickian) diffusion for the tablets released. It
is clear that the transfer cab be accepted because the drug release
in inter-laboratories has the samemechanism (Dash et al., 2010).
3.2.5. R-chart control approach
The result of R-chart control of sender lab was described in Fig. 3.
However, R-chart control based on dissolution data of sender in
three days for products A and B shows the variation in a measure-
ment during the time period namely three days that the dissolution
proﬁle is observed. This approach is performing to show how the
process capabilities are affected by changes to transfer of test. The
upper control limits of sender laboratory for products A and B
(8.40and7.75, respectively)aredrawnabove thecenterlineandoften
annotatedas ‘‘UCL’’.While the lower control limitsof sender lab for
products A and B (0.00 and 0.00, respectively) are drawn below the
centerline and often annotated as ‘‘LCL’’ (Baillargeon, 1997). On
the other hand, the variation of dissolution proﬁle of receiver labo-
ratorywasmeasuredbasedonR (inter-days) and the result showed
include R of receiver lab for products A and B (4.80 and 3.33,
respectively) within range of UCL and LCL of R-chart of sender
lab.This is due to the achievement andmaintaining the stability pro-Sender lab CICVIP Receiver lab CVIP
Inter-days
2.32 1.42 6 PI 6 2.84 2.50
1.45 1.12 6 PI 6 2.25 1.5
Day 3 Inter-days
2 f1 f2 f1 f2
4.82 3.70 66.13 4.04 66.12
6.12 1.19 65.87 2.04 68.70
Figure 3A R-chart control of dissolution data of sender labo-
ratory of product A.
Figure 3B R-chart control of dissolution data of sender labo-
ratory of product B.
Table 6 R-chart control to accept the transfer.
R-chart control
of sender lab
Sample rang
of receiver lab inter-days
UCL LCL Day 1 Day 2 Day 3 Inter-days
Product
A 8.40 0 3.2 7.7 3.6 4.80
B 7.95 0 3.6 2.4 3.8 3.33
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100 M.A. AL-Kamarany et al.cess of dissolution test data between sender and receiver laborato-
ries. Accordingly, this approach may be led to accept the trans-
fer of the dissolution method (Table 6).
4. Conclusion
The statistical procedure developed in this work can be used to ac-
cept transfer of dissolution test between sender and receiver labs
after development of dissolution condition. These approaches
could be used during analytical method development studies to
compare the proﬁles obtained using different dissolution test of in-
ter-laboratories to evaluate the gauge of repeatability, reproduc-
ibility bioequivalence in vitro and mechanism of drug release as
an easy and accurate way to their calculation. Also if the sender
used the total error to validate its analytical method, dissolution
test canbe successfully transferredwithoutmastering the analytical
method validation by receiving laboratory B.
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